Sarcomas | Specialty

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

FDA Accepts BLA for Denosumab Biosimilar for Reference Product Indications

February 6th 2023

The FDA has accepted for review a biologics license application for a proposed denosumab biosimilar, according to an announcement from Sandoz, Inc.

FDA Grants Breakthrough Therapy Designation for Pimicotinib in TGCT

January 30th 2023

The FDA has granted a breakthrough therapy designation to pimicotinib for the treatment of patients with tenosynovial giant cell tumor who are not amenable for surgery.

Pexidartinib With Surgery Proves Potential Benefit for Patients With Tenosynovial Giant Cell Tumors

January 7th 2023

R. Lor Randall, MD, FACS, discusses the outcomes of combining surgery and pexidartinib in patients with tenosynovial giant cell tumors, what investigators still need to learn about sequencing the CSF1R inhibitor around surgery, and what the combination approach could mean for patients with TGCT.

INT230-6 Alone, With Ipilimumab Induces Positive OS Results in Metastatic Sarcomas

December 30th 2022

INT230-6 demonstrated direct tumor killing in soft tissue sarcoma and elicits an anti-cancer immune response within the injected tumor both alone and in combination with ipilimumab.

Somaiah Shares Insight on the Changing Landscapes of GIST, TGCT, and RAS/RAF-Mutant Tumors

December 29th 2022

Dr Somaiah discusses the excitement surrounding novel agents such as CSF1R inhibitors and ULK1/2 inhibitors, and the utility of broad spectrum TKIs such as ripretinib.

3-Week Course of Radiotherapy May Offer Greater Convenience for Patients With Soft Tissue Sarcoma

December 29th 2022

Moderately hypofractionated preoperative radiotherapy did not increase risk for major wound complication in patients with soft tissue sarcomas, according to findings from the single-arm, phase 2 trial HYPORT-STS.

Randall Highlights Advances in Reconstruction Techniques for Patients With Bone Sarcomas

December 25th 2022

Robert Lawrence Randall, MD, FACS, discussed the role of biological reconstructions as well as factors that determine whether a patient would benefit more from the reconstructions or traditional prosthetics known as endoprosthetics.

Radiation Therapy Plus Surgery May Improve Local Control in Localized Pelvic Ewing Sarcoma

December 22nd 2022

R. Lor Randall, MD, FACS, discusses the significance of addition of surgery to radiation therapy led to improved local control compared with radiation therapy alone in patients with localized pelvic Ewing Sarcoma.

FDA Approves Atezolizumab for Alveolar Soft Part Sarcoma

December 9th 2022

The FDA has approved atezolizumab (Tecentriq) for adult and pediatric patients aged 2 years and older with unresectable or metastatic alveolar soft part sarcoma.

Afamitresgene Autoleucel Induces Durable Clinical Response in Advanced Synovial Sarcoma Or Myxoid/Round Cell Liposarcoma

November 23rd 2022

Afamitresgene autoleucel, a novel T-cell therapy, produced good clinical response lasting more than 4 years in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.

Camsirubicin Elicits Early Clinical Activity in Advanced Soft Tissue Sarcoma

November 18th 2022

Camsirubicin in combination with pegfilgrastim produced encouraging clinical activity and safety in patients with advanced soft tissue sarcoma.

Dr. Dzienis on Use of Pembrolizumab with Carboplatin and Paclitaxel in HNSCC

October 31st 2022

Marcin Dzienis, MD, discusses the use of pembrolizumab with carboplatin and paclitaxel in head and neck squamous cell carcinoma .

Salarius Pauses Phase 1/2 Trial Investigating Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas Following Death

October 19th 2022

Salarius Pharmaceuticals has voluntarily paused enrollment of new patients into a phase 1/2 trial investigating seclidemstat in patients with Ewing sarcoma, sarcomas with FET-family translocations, and myxoid liposarcoma due to the death of a patient.

177Lu-FAP-2286 Displays Preliminary Antitumor Activity in Advanced or Metastatic Solid Tumors

October 18th 2022

Lutetium-177-FAP-2286 produced preliminary evidence of antitumor activity with a manageable safety profile in patients with advanced or metastatic solid tumors, according to data from the phase 1/2 LuMIERE trial.

Dinutuximab Plus GM-CSF Does Not Improve DCR in Recurrent Osteosarcoma

October 16th 2022

R. Lor Randall, MD, FACS, discusses the poor prognosis associated with recurrent pulmonary osteosarcoma, the data from the AOST1421 trial of dinutuxumab plus granulocyte-macrophage colony-stimulating factor, and the need for expanded treatment options in osteosarcoma.

Socioeconomic Disparities Associated With Worse OS in Head and Neck Cutaneous Soft Tissue Sarcoma

October 11th 2022

R. Lor Randall, MD, FACS, discusses how disparities may lead to worse outcomes for patients diagnosed with head and neck cutaneous soft tissue sarcomas.

Phase 2 ENVASARC Trial of Envafolimab With and Without Ipilimumab in Sarcoma to Continue

October 7th 2022

An independent data monitoring committee has recommended that the phase 2 ENVASARC trial examining envafolimab with and without ipilimumab in patients with undifferentiated pleomorphic sarcoma and myxofibrosarcoma continue as planned.

FDA Grants Fast Track Designation to AL102 for Progressing Desmoid Tumors

September 27th 2022

The FDA has granted a fast track designation to AL102 for the treatment of patients with progressing desmoid tumors.

Desmoid Tumors: The Tumor That Isn’t a Cancer

September 27th 2022

Desmoid tumors, also known as aggressive fibromatosis, share some characteristics with cancers, specifically unchecked cell growth. However, it is not accurate to call them a cancer.

FDA Streamlines Regulatory Process for Envafolimab in Undifferentiated Pleomorphic Sarcoma and Myxofibrosarcoma

September 15th 2022

The FDA has granted a fast track designation to envafolimab for the treatment of patients with locally advanced, unresectable, or metastatic undifferentiated pleomorphic sarcoma and myxofibrosarcoma who have progressed on 1 or 2 prior lines of chemotherapy.